SCHEMBL197923

SCHEMBL197923

Cc1sc(C2(c3ccc(C(=O)NO)cc3)CCOCC2)nc1-c1cnc2ccccn12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 5/20 0.39
HDAC3 O15379 4/20 0.39
HDAC2 Q92769 4/20 0.39
HDAC6 Q9UBN7 4/20 0.39
IGF1R P08069 3/20 0.39
KCNH2 Q12809 3/20 0.39
MARK3 P27448 1/20 0.38
PIK3CA P42336 2/20 0.38
PIK3CB P42338 2/20 0.38
PIK3CD O00329 1/20 0.38
MTOR P42345 1/20 0.38
PIP4K2A P48426 1/20 0.38
PIK3CG P48736 1/20 0.38
VPS35 Q96QK1 1/20 0.38
PIK3R4 Q99570 1/20 0.38
PI4KB Q9UBF8 1/20 0.38
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3354200 0.94 PIK3CA (0.40) HDAC1HDAC3HDAC6MARK3PIK3CA
SCHEMBL3356956 0.92 MARK3 (0.41) HDAC1HDAC3HDAC2HDAC6MARK3
SCHEMBL197554 0.88 HDAC1 (0.48) HDAC1HDAC3HDAC2HDAC6PIK3CA
SCHEMBL197516 0.86 GAA (0.39) HDAC1HDAC3HDAC2HDAC6NPC1
SCHEMBL3353327 0.85 MARK3 (0.39) HDAC1HDAC3HDAC2HDAC6MARK3
SCHEMBL198016 0.84 PKM (0.45) HDAC1HDAC3HDAC2HDAC6IGF1R
SCHEMBL3357410 0.82 HDAC1 (0.51) HDAC1HDAC2MARK3PIK3CAPIK3CB
SCHEMBL3357440 0.81 HDAC1 (0.49) HDAC1HDAC2MARK3PIK3CAPIK3CB
SCHEMBL3348291 0.79 AKT1 (0.38) HDAC1ALDH1A1MAPTHPGD
SCHEMBL3350719 0.78 AKT1 (0.39) ALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088771-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-01-03 US claimed
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 HDAC1 1/4885HDAC3 4/4885HDAC2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.